Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Afuresertib + LAE001 + Prednisone |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Afuresertib | GSK2110183|GSK-2110183 | Akt Inhibitor (Pan) 21 AKT Inhibitor (Pan) - ATP competitive 7 | Afuresertib (GSK2110183) is a pan-AKT, ATP-competitive inhibitor, which may result in inhibition of the PI3K/AKT signaling pathway and tumor cell proliferation, and induction of tumor cell apoptosis (PMID: 25075128, PMID: 30563934). | |
LAE001 | LAE-001|LAE 001|CFG920|CFG-920|CFG 920 | Hormone - Anti-androgens 54 | LAE001 (CFG920) inhibits CYP17, resulting in decreased androgen production and potentially leading to reduced proliferation of androgen-dependent tumor cells (PMID: 23880851, PMID: 26954621). | |
Prednisone | Adasone | Dehydrocortisone | Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04060394 | Phase Ib/II | Afuresertib + LAE001 + Prednisone Afuresertib | Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC | Completed | USA | 1 |